Research Breakthrough Stories
What this page covers
Developed a groundbreaking CAR-T cell therapy that targets previously untreatable pancreatic cancer cells
This page was restored into the green AcademicWings product surface. Prefer official university and government pages for requirements that change over time.
- Novel T-Cell Therapy for Pancreatic Cancer
- 85% remission rate in clinical trials, now FDA-approved
- Developed a groundbreaking CAR-T cell therapy that targets previously untreatable pancreatic cancer cells
- Overcoming immune system rejection and finding the right cell markers
- $15M NIH Grant + $8M Private Funding
- 25 papers in Nature, Science, Cell
- 3 patents filed, 2 approved
- Every failed experiment brought us closer to understanding what cancer cells can't hide from.
Useful next pages
Verify with primary pages
Legacy page source
Imported from client/src/pages/resources-research-breakthrough-stories.tsx. Verify current requirements on official destinations.
Legacy marketing claims adjusted
85% remission rate in clinical trials, now FDA-approved
removed · Unsourced legacy marketing figure omitted during green migration.
4,500+ citations
removed · Unsourced legacy marketing figure omitted during green migration.
3,800+ citations
removed · Unsourced legacy marketing figure omitted during green migration.
Could reduce global CO2 emissions by 8% if widely adopted
removed · Unsourced legacy marketing figure omitted during green migration.
2,900+ citations
removed · Unsourced legacy marketing figure omitted during green migration.
Deployed in 200+ construction projects across 30 countries
removed · Unsourced legacy marketing figure omitted during green migration.
Paralyzed patients can control devices with 95% accuracy
removed · Unsourced legacy marketing figure omitted during green migration.
5,200+ citations
removed · Unsourced legacy marketing figure omitted during green migration.